Liquidia (LQDA) reported $158M in revenue for fiscal 2025, +1,031.2% year on year. That ranks #2765 by revenue among 2853 SEC filers and #304 in Healthcare. It posted a net loss of −$68.9M for the same year. Revenue has grown 64.2% a year on average since 2019 ($8.1M then). The fiscal 2025 balance sheet shows $328M in total assets, $191M in cash and $19.9M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $158M | +1,031.2% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$51.4M | +$69.9M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$68.9M | +$61.5M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$35.7M | +$57.7M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $4.3M | −12.4% | FY20252025-12-31 |
| Total assetsAssets | $328M | +42.4% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $44.7M | −43.6% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $191M | +8.0% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $19.9M | +91.0% | FY20222022-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $133M | $52.9M | Open → |
| Q2 20262026-06-30 | $172M | $74.7M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Liquidia Corp
- Ticker
- LQDA
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001819576
Filings
- 10-QAug 12, 2026Open filing →
- 10-QMay 11, 2026Open filing →
- 10-KMar 5, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| RegenxbioRGNX | $170M | −$194M |
| Ginkgo BioworksDNA | $170M | −$313,000 |
| MarimedMRMD | $160M | −$14.5M |
| LiquidiaLQDA | $158M | −$68.9M |
| Heron TherapeuticsHRTX | $155M | −$20.0M |
| Airsculpt TechnologiesAIRS | $152M | −$11.7M |
| MacrogenicsMGNX | $150M | −$74,620 |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Liquidia — Key figures |url=https://companiesranked.com/en/company/liquidia |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Liquidia — Key figures. CompaniesRanked. https://companiesranked.com/en/company/liquidiaBibTeX
@misc{companiesranked-en-company-liquidia-2026,
author = {{CompaniesRanked}},
title = {{Liquidia — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/liquidia}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001104659-26-023804 · March 5, 2026
{{cite web |title=Liquidia — Key figures — 10-K (0001104659-26-023804) |url=https://www.sec.gov/Archives/edgar/data/1819576/000110465926023804/lqda-20251231x10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-05}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.